Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate

Cephalalgia

Volumn 30, Issue 11, 2010, Pages 1283-

  Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE;

DRUG WITHDRAWAL; EDITORIAL; HUMAN; MIGRAINE; OPEN STUDY; RELAPSE;

FRUCTOSE; HUMANS; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 79751490333     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410383060     Document Type: Editorial

References (3)

1. Jean Schoenen, Uwe Reuter, Hans-Christoph Diener, Joop Pfeil, Susanne Schwalen, Barbara Schäuble, et al. Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia, published online ahead of print March 2010 ; doi:10.1177/ 0333102409359709.
2. Diener HC, Agosti R., Allais G., Bergmans P., Bussons G., Davies B., et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007 ; 6: 1054-1062. (Pubitemid 350123606)
3. Stephen D. Silberstein, MD, FACP, for the US Headache Consortium Practice parameter: Evidence-based guidelines for migraidane headache (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 ; 55: 754-763.